Experience Formae: Fill & Download for Free

Chandigarh Zada syi ae bhai. Personal experience ae halke m matt lena.LPU bhi achii ae lekin Chandigarh University m mere kyi friends LPU shodkr aye ae unone btaya ki CU pdhai ke mamle m CU zada achha LPU m sirf chkachaund e ae.

These are the 8 most common sales mistakes that I frequently notice in venture-funded SaaS startups (particularly from Series A to Series C) :Hire a bunch of closers when there is no pipeline - These experience AEs spend all of their time trying to get a meeting, their pitch is terrible because they haven’t practiced it enough, and after a few months they get frustrated and leave. → It’s better to beef up the SDR team at the beginning and have only one rep (or the CEO) to close the deals.Hire AE and SDR hybrids - These are people who need to prospect and generate their own pipeline, then close it. They can’t do both at the same time, so they’ll spend half of the quarter trying to create pipeline, then the other half trying to close it. Then they start the next quarter with zero pipeline. This can work if your sales cycle is 45 days or less (not common in SaaS). → Start specializing roles from the beginning.Establish quota way too high - When I look at some of the forecast for the fiscal year, the only way to make it is by either hiring twice as many reps or expecting that everyone will double their quota (which is already high to begin with). After two quarters of missing quota, even your best rep will leave as he/she is making no money. → Be realistic with what is an attainable quota at your stage.Having no formal onboarding or training - I believe only 20% or less of SaaS startups have a formal training program in place for new reps. For the majority, training means “here’s some videos to watch, read these whitepapers and shadow one of the other reps until you are ready”. → Invest in this as early as you can, have a program in place that covers their first month with classes and tests, your ramp time will decrease significantly. Also, if you are hiring more than one rep, hire them in classes.Have SDRs acting as the “executive assistants” of field reps - It’s good to pair the SDRs with the field reps, but their role needs to be well defined and written down on a playbook. It’s not the SDR’s role to do data entry for the rep or to manage his/her calendar → Define the SDR process for both mid-market and enterprise and monitor it. Make expectations clear from the beginning.Implement territories too early - Your sales process changes frequently at the beginning. Maybe you were initially targeting manufacturing companies, now you found out that your best vertical is telecommunication or banking. If what drives your process is territories, you’ll have to adjust who you are targeting so that you don’t leave a few reps without prospects (even though they are not your ideal customer profiles). → Implement territories as late as you can. I know companies with 15 reps and still no territories (and they are doing really well). You can still hire reps in different regions, but don’t be strict with the territory division at the begging, go by target account lists.Have a messy sales funnel - You should know exactly how your leads are going through the funnel, how they get assigned, converted into opportunities, recycle. Often, companies leave hundreds of thousands of leads parked in some “queues” that are then forgotten. → Hire a demand generation or sales ops expert at the beginning to map and monitor these processes.Not automating mindless tasks - Don’t have your SDRs or AEs spend their time building lists or performing repetitive tasks. That’s a huge waste of money. → If you can, automate them via Marketo, Outreach, etc. If not, outsource them.

Is it reasonable? What, exactly, else would you need to know to feel assured that the vaccines are safe?As of today, April 13, in the United States alone there have been over 190 million vaccine doses administered. [1] According to the VAERS database, which tracks any and all adverse events associated with vaccination, there have been 46164 adverse events that have followed vaccine administration for any of the three EUA granted vaccines in the US (Janssen, Moderna, BioNTech/Pfizer) as well as any other vaccine since January 1 of this year.[2] That’s an AE rate of 0.0243% per shot for all vaccines - it includes things like Shingrix and Flu and Pneumovax. So when do AEs happen after the shot? Here’s my analysis of number of adverse events vs days since getting the injection:Another way to show this:The vast, overwhelming majority of AEs occur on the same day or the day after getting a shot. There are a handful of people who experience AEs within a week, and a small fraction who experience one within two weeks. Almost no one experiences any adverse events after two weeks. There is virtually no risk of long-term adverse events emerging from vaccination, so no longer period of observation is required.Which is pretty damned good - it means that you have about a 3 in 10000 chance of having any adverse reaction at all to any vaccine, which is phenomenally good, and it’s actually even lower than that because we know the number of injections but not how many AEs are due only to COVID vaccination, but it’s less. And if you do have an adverse reaction, it will almost certainly happen within the first two weeks of getting an injection, and very likely on that same day or the next day.So we’ve established the risk level of the vaccine. But medicine is all about balancing risks - if you really want to look at this quantitatively, you need to balance the risk of being vaccinated with the risk of not being vaccinated.In the United States, as of April 13 there have been a total of 31273951 infections, which represents 10.6% of the total population. There have been 562655 deaths, which means that there is a 1.8% case fatality rate. As a function of the general population, that means that overall risk of death from COVID in the United States is 0.29%. That’s just death, we’re not even looking into short or potentially long-term complications of COVID infection, and we’re also not taking into account that chance that you may infect someone else and give them a serious complication or death from COVID.Now think back to the earlier term we calculated - there was a 0.0243% chance of experiencing any reported adverse event from a vaccine, and the number for COVID vaccines is lower. That includes things like headaches, having a rash, getting flushed, feeling fatigue, or nausea, or potentially more serious complications.From a general statistical perspective, if you live in the US you are 12 times more likely to die from COVID than to have a serious adverse event from a COVID vaccine. Which seems to make the risk/benefit calculation pretty straightforward.Now yes, it’s true that this is general across the entire population and the specific risk of a COVID infection for an individual will vary based on things like age and comorbidities. If someone would like to also calculate the specific risk of developing a serious adverse event from a vaccine based on those same comorbidities and compare relative risks, by all means, I’d like to see that done. I don’t have the data to do it.That’s the data that we have right now from the currently available vaccines. If that’s not good enough to convince you that it’s worth being vaccinated, you should ask yourself what you would need to see to do so. If the answer is “nothing” then it may be time to reevaluate your priorities in general.Footnotes[1] More Than 797 Million Shots Given: Covid-19 Tracker[2] Download Data File